Namilumab or infliximab compared to standard of care in hospitalised patients with COVID-19 (CATALYST): a phase 2 randomised adaptive trial

Fisher BA., Veenith T., Slade D., Gaskell C., Rowland M., Whitehouse T., Scriven J., Parekh D., Balasubramaniam MS., Cooke G., Morley N., Gabriel Z., Wise MP., Porter J., McShane H., Ho L-P., Newsome PN., Rowe A., Sharpe R., Thickett DR., Bion J., Gates S., Richards D., Kearns P.

DOI

10.1101/2021.06.02.21258204

Type

Preprint

Publication Date

2021-06-09T00:00:00+00:00

Permalink More information Close